Loading...
XNYS
IQV
Market cap38bUSD
Dec 05, Last price  
225.85USD
1D
0.41%
1Q
20.34%
Jan 2017
196.98%
IPO
432.79%
Name

IQVIA Holdings Inc

Chart & Performance

D1W1MN
XNYS:IQV chart
P/E
28.01
P/S
2.50
EPS
8.06
Div Yield, %
Shrs. gr., 5y
-1.68%
Rev. gr., 5y
6.80%
Revenues
15.41b
+2.81%
3,924,020,0004,327,748,0004,865,513,0005,099,545,0005,459,998,0005,737,619,0006,878,000,0009,739,000,00010,412,000,00011,088,000,00011,359,000,00013,874,000,00014,410,000,00014,984,000,00015,405,000,000
Net income
1.37b
+1.10%
160,596,000241,772,000177,546,000226,591,000356,383,000387,205,000115,000,0001,309,000,000259,000,000191,000,000279,000,000966,000,0001,091,000,0001,358,000,0001,373,000,000
CFO
2.72b
+26.38%
378,160,000160,953,000335,701,000397,370,000431,754,000475,691,000860,000,000970,000,0001,254,000,0001,417,000,0001,959,000,0002,942,000,0002,260,000,0002,149,000,0002,716,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IPO date
May 09, 2013
Employees
87,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT